Compare Stocks: DYAI, GANX, OKYO, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.46 +6.1%	$0.67	$0.34 ▼ $1.60	$17.21M	0.96	192,908 shs	142,057 shs
GANX Gain Therapeutics	$1.71 -0.6%	$1.83	$1.53 ▼ $4.34	$75.07M	0.19	426,727 shs	383,504 shs
GOSS Gossamer Bio	$10.71 -2.0%	$12.95	$9.10 ▼ $309.60	$66.79M	2.21	297,395 shs	235,003 shs
OKYO OKYO Pharma	$1.47 +9.7%	$1.50	$1.26 ▼ $3.20	$70.32M	0.05	83,267 shs	82,518 shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	-3.37%	-1.29%	-19.26%	-54.32%	-66.95%
GANX Gain Therapeutics	-0.58%	-6.52%	-2.82%	-9.95%	-5.49%
GOSS Gossamer Bio	-7.76%	0.00%	-18.38%	-21.12%	-94.51%
OKYO OKYO Pharma	+2.79%	-3.91%	-12.19%	-15.54%	-34.03%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DYAI Dyadic International	$0.46 +6.1%	$0.67	$0.34 ▼ $1.60	$17.21M	0.96	192,908 shs	142,057 shs
GANX Gain Therapeutics	$1.71 -0.6%	$1.83	$1.53 ▼ $4.34	$75.07M	0.19	426,727 shs	383,504 shs
GOSS Gossamer Bio	$10.71 -2.0%	$12.95	$9.10 ▼ $309.60	$66.79M	2.21	297,395 shs	235,003 shs
OKYO OKYO Pharma	$1.47 +9.7%	$1.50	$1.26 ▼ $3.20	$70.32M	0.05	83,267 shs	82,518 shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DYAI Dyadic International	-3.37%	-1.29%	-19.26%	-54.32%	-66.95%
GANX Gain Therapeutics	-0.58%	-6.52%	-2.82%	-9.95%	-5.49%
GOSS Gossamer Bio	-7.76%	0.00%	-18.38%	-21.12%	-94.51%
OKYO OKYO Pharma	+2.79%	-3.91%	-12.19%	-15.54%	-34.03%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DYAI Dyadic International	2.00	Hold	$3.00	558.18% Upside
GANX Gain Therapeutics	2.67	Moderate Buy	$7.50	338.60% Upside
GOSS Gossamer Bio	2.22	Hold	$256.00	2,290.29% Upside
OKYO OKYO Pharma	2.50	Moderate Buy	$5.67	285.49% Upside

Current Analyst Ratings Breakdown

Latest DYAI, GANX, OKYO, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/4/2026	GANX Gain Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/31/2026	GANX Gain Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/12/2026	DYAI Dyadic International	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	GANX Gain Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$80.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	OKYO OKYO Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DYAI Dyadic International	$3.09M	5.91	N/A	N/A	$0.03 per share	15.19
GANX Gain Therapeutics	$50K	1,492.49	N/A	N/A	$0.48 per share	3.56
GOSS Gossamer Bio	$48.47M	1.35	N/A	N/A	($42.43) per share	-0.25
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	$0.30 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DYAI Dyadic International	-$7.36M	-$0.23	N/A	N/A	N/A	-201.43%	-2,920.31%	-84.77%	11/11/2026 (Estimated)
GANX Gain Therapeutics	-$20.16M	-$0.50	N/A	N/A	N/A	N/A	-161.59%	-118.36%	11/11/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
OKYO OKYO Pharma	-$8.95M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	12/2/2026 (Estimated)

Latest DYAI, GANX, OKYO, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2026	Q2 2026	DYAI Dyadic International	-$0.0350	-$0.06	-$0.0250	-$0.06	$1.03 million	$0.96 million
8/11/2026	Q2 2026	GANX Gain Therapeutics	-$0.1380	-$0.11	+$0.0280	-$0.11	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DYAI Dyadic International	N/A	N/A	N/A	N/A	N/A
GANX Gain Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DYAI Dyadic International	N/A	1.65	1.65
GANX Gain Therapeutics	0.02	4.36	4.36
GOSS Gossamer Bio	N/A	0.53	0.53
OKYO OKYO Pharma	N/A	2.43	2.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DYAI Dyadic International	27.95%
GANX Gain Therapeutics	11.97%
GOSS Gossamer Bio	81.23%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
DYAI Dyadic International	20.90%
GANX Gain Therapeutics	4.15%
GOSS Gossamer Bio	4.15%
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DYAI Dyadic International	5	40.06 million	31.69 million	Optionable
GANX Gain Therapeutics	21	43.64 million	41.83 million	Optionable
GOSS Gossamer Bio	162	6.11 million	5.86 million	Optionable
OKYO OKYO Pharma	5	52.48 million	31.25 million	Not Optionable

DYAI, GANX, OKYO, and GOSS Headlines

Recent News About These Companies

OKYO Pharma Presents and Participates at Upcoming Ophthalmic Scientific Conferences

September 29 at 7:00 AM | globenewswire.com

OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026

September 9, 2026 | globenewswire.com

OKYO Pharma to Participate in a Fireside Chat at the Cantor Global Healthcare Conference

September 8, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

July 28, 2026 | globenewswire.com

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

July 27, 2026 | globenewswire.com

OKYO Pharma outlines path to phase 3 NEPTUNE trial of urcosimod for neuropathic corneal pain

July 25, 2026 | ophthalmologytimes.comO

OKYO Pharma Announces Purchase of Shares by Director

July 23, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

July 23, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chairman

July 22, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

July 22, 2026 | globenewswire.com

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

July 22, 2026 | globenewswire.com

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

July 21, 2026 | markets.businessinsider.com

OKYO Pharma Announces Purchase of Shares by Chairman

July 21, 2026 | globenewswire.com

Small caps: Replenish Nutrients, OKYO Pharma, EDM Resources

July 20, 2026 | proactiveinvestors.com

OKYO Pharma files annual report, highlights cash position and Phase 3 trial plans

July 20, 2026 | proactiveinvestors.com

OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans

July 20, 2026 | globenewswire.com

OKYO Pharma to Highlight Neuropathic Corneal Pain Program at Piper Sandler Virtual Ophthalmology Symposium

July 14, 2026 | theglobeandmail.com

OKYO Pharma announces positive feedback from US FDA Type D Meeting and accelerates urcosimod into global phase 3 trial for NCP

July 11, 2026 | pharmabiz.comP

OKYO Pharma advances toward Phase 3 FDA trial - ICYMI

July 11, 2026 | proactiveinvestors.com

Phase 3 trial to study urcosimod in neuropathic corneal pain

July 10, 2026 | healio.comH

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI, GANX, OKYO, and GOSS Company Descriptions

Dyadic International NASDAQ:DYAI

$0.46 +0.03 (+6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.92%)

As of 07:13 PM Eastern

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Gain Therapeutics NASDAQ:GANX

$1.71 -0.01 (-0.58%)

Closing price 04:00 PM Eastern

Extended Trading

$1.75 +0.04 (+2.11%)

As of 07:59 PM Eastern

Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

Gossamer Bio NASDAQ:GOSS

$10.71 -0.22 (-2.01%)

Closing price 04:00 PM Eastern

Extended Trading

$10.82 +0.11 (+1.03%)

As of 07:30 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

OKYO Pharma NASDAQ:OKYO

$1.47 +0.13 (+9.70%)

Closing price 04:00 PM Eastern

Extended Trading

$1.45 -0.02 (-1.36%)

As of 07:30 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYAI, GANX, OKYO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYAI, GANX, OKYO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYAI, GANX, OKYO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI, GANX, OKYO, and GOSS Company Descriptions

Dyadic International NASDAQ:DYAI

Gain Therapeutics NASDAQ:GANX

Gossamer Bio NASDAQ:GOSS

OKYO Pharma NASDAQ:OKYO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DYAI, GANX, OKYO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DYAI, GANX, OKYO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DYAI, GANX, OKYO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI, GANX, OKYO, and GOSS Company Descriptions

Dyadic International NASDAQ:DYAI

Gain Therapeutics NASDAQ:GANX

Gossamer Bio NASDAQ:GOSS

OKYO Pharma NASDAQ:OKYO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools